Jih-Hua Wei1,2,3, Wei-Jei Lee4, Keong Chong1, Yi-Chih Lee5, Shu-Chun Chen6, Po-Hsun Huang2,7,8, Shing-Jong Lin2,8. 1. Department of Internal Medicine, Min-Sheng General Hospital, Taoyuan, Taiwan. 2. Institute of Clinical Medicine, National Yang Ming University, Taipei, Taiwan. 3. Department of Nutrition and Health Sciences, School of Healthcare Management, Kai-Nan University, Taoyuan, Taiwan. 4. Department of Surgery, Min-Sheng General Hospital, No. 168, Chin Kuo Road, Tauoyan, Taiwan, Republic of China. wjlee_obessurg_tw@yahoo.com.tw. 5. Department of International Business, Chien Hsin University of Science and Technology, Taoyuan, Taiwan. 6. Department of Surgery, Min-Sheng General Hospital, No. 168, Chin Kuo Road, Tauoyan, Taiwan, Republic of China. 7. Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan. 8. Division of Cardiovascular Medicine, Department of Internal medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
Abstract
BACKGROUND: Bariatric surgery is an effective therapy for morbid obesity but may reduce calcium absorption and significantly decrease the bone mineral density. This study examined the prevalence of secondary hyperparathyroidism (SHPT) in obese subjects during follow-up after different bariatric surgeries. We investigated predictors of SHPT. METHODS: We enrolled 1470 obese subjects undergoing bariatric/metabolic surgery with at least 1-year follow-up, including 322 patients undergoing Roux-en-Y gastric bypass (RYGB), 695 undergoing single anastomosis (mini-) gastric bypass (SAGB), 93 undergoing laparoscopic adjustable gastric banding (LAGB), and 360 undergoing sleeve gastrectomy (SG). Five years of data were available for 215 patients. Patients were instructed to supplement their diet according to the guideline. Calcium, parathyroid hormone (PTH), and vitamin D levels were measured before surgery and at 1 and 5 years after surgery. SHPT was defined as PTH > 69 pg/mL. RESULTS: The overall prevalence of SHPT was high, 21.0% before surgery and was not different between patients with different bariatric procedures. Pre-operative PTH correlated with age, BMI, and vitamin D levels. Multi-variate analysis confirmed that vitamin D level was the only independent predictor of SHPT before surgery. The prevalence of SHPT increased to 35.4% at 1 year after surgery and 63.3% at 5 years after surgery. SAGB had the highest prevalence of SHPT (50.6%) followed by RYGB (33.2%), LAGB (25.8%), and SG (17.8%) at 1 year after surgery. At 5 years after surgery, SAGB still had the highest prevalence of SHPT (73.6%), followed by RYGB (56.6%), LAGB (38.5%), and SG (41.7%). Serum PTH at 1 year after surgery correlated with decreased BMI and weight loss. Multi-variate analysis confirmed that age, sex, calcium level, and bypass procedure were independent predictor of SHPT after surgery. CONCLUSIONS: The prevalence of SHPT is high in morbidly obese patients before bariatric surgery which is related to vitamin D deficiency. The prevalence of SHPT increased continually along with the time after bariatric surgery, especially in patients receiving SAGB, followed by RYGB. The supplementation of vitamin D and calcium have to be higher in bypass procedure, especially in malabsorptive procedure.
BACKGROUND: Bariatric surgery is an effective therapy for morbid obesity but may reduce calcium absorption and significantly decrease the bone mineral density. This study examined the prevalence of secondary hyperparathyroidism (SHPT) in obese subjects during follow-up after different bariatric surgeries. We investigated predictors of SHPT. METHODS: We enrolled 1470 obese subjects undergoing bariatric/metabolic surgery with at least 1-year follow-up, including 322 patients undergoing Roux-en-Y gastric bypass (RYGB), 695 undergoing single anastomosis (mini-) gastric bypass (SAGB), 93 undergoing laparoscopic adjustable gastric banding (LAGB), and 360 undergoing sleeve gastrectomy (SG). Five years of data were available for 215 patients. Patients were instructed to supplement their diet according to the guideline. Calcium, parathyroid hormone (PTH), and vitamin D levels were measured before surgery and at 1 and 5 years after surgery. SHPT was defined as PTH > 69 pg/mL. RESULTS: The overall prevalence of SHPT was high, 21.0% before surgery and was not different between patients with different bariatric procedures. Pre-operative PTH correlated with age, BMI, and vitamin D levels. Multi-variate analysis confirmed that vitamin D level was the only independent predictor of SHPT before surgery. The prevalence of SHPT increased to 35.4% at 1 year after surgery and 63.3% at 5 years after surgery. SAGB had the highest prevalence of SHPT (50.6%) followed by RYGB (33.2%), LAGB (25.8%), and SG (17.8%) at 1 year after surgery. At 5 years after surgery, SAGB still had the highest prevalence of SHPT (73.6%), followed by RYGB (56.6%), LAGB (38.5%), and SG (41.7%). Serum PTH at 1 year after surgery correlated with decreased BMI and weight loss. Multi-variate analysis confirmed that age, sex, calcium level, and bypass procedure were independent predictor of SHPT after surgery. CONCLUSIONS: The prevalence of SHPT is high in morbidly obesepatients before bariatric surgery which is related to vitamin D deficiency. The prevalence of SHPT increased continually along with the time after bariatric surgery, especially in patients receiving SAGB, followed by RYGB. The supplementation of vitamin D and calcium have to be higher in bypass procedure, especially in malabsorptive procedure.
Authors: Jason M Johnson; James W Maher; Eric J DeMaria; Robert W Downs; Luke G Wolfe; John M Kellum Journal: Ann Surg Date: 2006-05 Impact factor: 12.969
Authors: Sayeed Ikramuddin; Charles J Billington; Wei-Jei Lee; John P Bantle; Avis J Thomas; John E Connett; Daniel B Leslie; William B Inabnet; Robert W Jeffery; Keong Chong; Lee-Ming Chuang; Michael G Sarr; Michael D Jensen; Adrian Vella; Leaque Ahmed; Kumar Belani; Joyce L Schone; Amy E Olofson; Heather A Bainbridge; Patricia S Laqua; Qi Wang; Judith Korner Journal: Lancet Diabetes Endocrinol Date: 2015-05-12 Impact factor: 32.069
Authors: Maurizio De Luca; Luigi Angrisani; Jacques Himpens; Luca Busetto; Nicola Scopinaro; Rudolf Weiner; Alberto Sartori; Christine Stier; Muffazal Lakdawala; Aparna G Bhasker; Henry Buchwald; John Dixon; Sonja Chiappetta; Hans-Christian Kolberg; Gema Frühbeck; David B Sarwer; Michel Suter; Emanuele Soricelli; Mattias Blüher; Ramon Vilallonga; Arya Sharma; Scott Shikora Journal: Obes Surg Date: 2016-08 Impact factor: 4.129
Authors: David Edholm; Felicity Svensson; Ingmar Näslund; F Anders Karlsson; Eva Rask; Magnus Sundbom Journal: Surg Obes Relat Dis Date: 2012-03-23 Impact factor: 4.734
Authors: Penelope S Coates; John D Fernstrom; Madelyn H Fernstrom; Philip R Schauer; Susan L Greenspan Journal: J Clin Endocrinol Metab Date: 2004-03 Impact factor: 5.958
Authors: Christos Karefylakis; Ingmar Näslund; David Edholm; Magnus Sundbom; F Anders Karlsson; Eva Rask Journal: Obes Surg Date: 2014-03 Impact factor: 4.129
Authors: Arief Lalmohamed; Frank de Vries; Marloes T Bazelier; Alun Cooper; Tjeerd-Pieter van Staa; Cyrus Cooper; Nicholas C Harvey Journal: BMJ Date: 2012-08-03
Authors: Fernando Guerrero-Pérez; Anna Casajoana; Carmen Gómez-Vaquero; Nuria Virgili; Rafael López-Urdiales; Laura Hernández-Montoliu; Jordi Pujol-Gebelli; Javier Osorio; Carolina Alves; Manuel Perez-Maraver; Silvia Pellitero; Anna Vidal-Alabró; Sonia Fernández-Veledo; Joan Vendrell; Nuria Vilarrasa Journal: Obes Surg Date: 2020-01 Impact factor: 4.129
Authors: C Gronnier; F Tremollieres; Blandine Gatta-Cherifi; O Cadart; O Degrandi; T Barnetche; N Mehsen-Cetre; M Monsaingeon-Henry; E Pupier; L Bosc; D Collet Journal: Obes Surg Date: 2020-09 Impact factor: 4.129